Contact Us marketing@medicilon.com
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
SERVICES
SERVICES
01 Drug Discovery
Chemistry Research Biology Research Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates Active Pharmaceutical Ingredients Pharmaceutical preparation Analytical Method Development and Quality Control CMC Filings Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics Drug Safety Evaluation DMPK Bioanalysis IND Filings
PLATFORM
PLATFORM
01 One-stop Integrated Services
Liposome Drug Development Drug Discovery Pharmaceutical Research Preclinical Research Botanical Drug Preclinical R&D
02 Innovative Drug R&D Services
Peptide Drug Conjugate (PDC) Antibody Nucleic Acid Drug Cellular Immunotherapies mRNA Vaccine PROTAC ADC
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Metabolite Identification (MetID) Drug Forming Research Flow Cytometry Technology SEND Format Conversion Flow Sorting NanoString nCounter Detection Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
Rodent Cerebrovascular Disease Inflammatory and Immune Diseases IO Pharmacodynamic Model
05 High-end Preparations Technology Platform
Skin Topical Preparation Ophthalmic drug Inhalation drug
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service KRAS-targeted Drugs R&D Service GLP-1 New Drug R&D Service
07 Safety Assessment Lab of Process Chemistry

08 Public Services
CAREERS
Talent Development
Campus Recruitment
Recruitment
NEWS
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
INVESTORS
Stock Information
Investment Contact
CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
CN
×
中
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsMedicilon Events

Medicilon Events

Hot information：
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model
Jun 08,2023
Medicilon was honored again the "Top Ten Drug Innovation Service Institutions of the Year" of the Pharmaceutical Innovation Award
Recently, the "3rd Pharmaceutical Innovation Award", was released. Medicilon was honored again the "Top Ten Drug Innovation Service Institutions of the Year".
More
Medicilon was honored again the "Top Ten Drug Innovation Service Institutions of the Year" of the Pharmaceutical Innovation Award
Jun 05,2023
Congratulations to Gluetacs Therapeutics' new drug clinical research application for GT919, the first molecular glue degradation agent pipeline, approved by the FDA
Recently, Gluetacs Therapeutics (Gluetacs)'s first class 1 new drug, GT919 Capsules, a molecular glue degradation agent pipeline, was approved by the US Food and Drug Administration (FDA) to enter clinical trials. Medicilon's one-stop preclinical R&D service platform empowering new drug research and development.
More
Congratulations to Gluetacs Therapeutics' new drug clinical research application for GT919, the first molecular glue degradation agent pipeline, approved by the FDA
Jun 05,2023
Medicilon interviewed Academician Biao Jiang | Co-founded Gluetacs Therapeutics to transform the scientific and technological achievements sleeping in the ivory tower
For this reason, Shanghai Medicilon Inc (Medicilon) interviewed Academician Jiang to see how he overcomes the problems of transformation of scientific and technological achievements, how to improve the efficiency of new drug research and development, and how to be a scientist and entrepreneur.
More
Medicilon interviewed Academician Biao Jiang | Co-founded Gluetacs Therapeutics to transform the scientific and technological achievements sleeping in the ivory tower
May 25,2023
Medicilon interview with Dr. Yingfu Li - With the innovation ability in the left hand and the growth ability in the right hand, what does Hyperway Pharmaceuticals, which has only been established for 4 years, rely on it?
Shanghai Medicilon Inc. (Medicilon), as a partner of Hyperway, invited Dr. Yingfu Li, the founder of Hyperway, to reveal the secrets of Hyperway's innovation and growth.
More
Medicilon interview with Dr. Yingfu Li - With the innovation ability in the left hand and the growth ability in the right hand, what does Hyperway Pharmaceuticals, which has only been established for 4 years, rely on it?
May 12,2023
Medicilon has been listed in the "2022 China Biopharmaceutical Innovation Billboard" for two consecutive years, and won the "Golden Horse Award - 2022 Best Preclinical CRO/CDMO Enterprise"
Shanghai Medicilon Inc (Medicilon) stands out among many CROs in the country by virtue of advanced R&D technology, innovative service platform, outstanding performance and excellent market reputation, as a result, Medicilon is awarded the "Golden Horse Award - 2022 Best Preclinical CRO/CDMO Enterprise."
More
Medicilon has been listed in the "2022 China Biopharmaceutical Innovation Billboard" for two consecutive years, and won the "Golden Horse Award - 2022 Best Preclinical CRO/CDMO Enterprise"
Apr 26,2023
Medicilon's newly added facilities have obtained the GLP certification qualification of the National Medical Products Administration
On April 20, Medicilon Preclinical Research (Shanghai) LLC (MPR), has obtained the GLP (Good Laboratory Practice) certification of the National Medical Products Administration (NMPA) for the newly added facilities at Nanhui Park.
More
Medicilon's newly added facilities have obtained the GLP certification qualification of the National Medical Products Administration
Apr 10,2023
Medicilon was selected into the "2023 Shanghai Hardcore Technology Enterprises TOP 100 List"
Shanghai Medicilon Inc. stood out from more than 1,500 outstanding companies and was successfully selected into the list of "2023 Shanghai Hardcore Technology Enterprises TOP 100 List". The recognition of Shanghai's hard-core technology enterprise is the official recognition of Medicilon's comprehensive R&D technology innovation, technical service platform, and drug R&D empowerment.
More
Medicilon was selected into the "2023 Shanghai Hardcore Technology Enterprises TOP 100 List"
Mar 14,2023
Medicilon Assists Xuanzhu Biopharmaceutical's KM501, a First Double-antibody ADC Drug that Completely Knocks Out Fucose, has been Approved for Clinical Trials
Recently, Xuanzhu Biopharmaceutical (Xuanzhu) and its wholly-owned subsidiary Beijing Xuanzhu Bio, obtained clinical trial approval for the double-antibody ADC drug KM501 (No.: 2023LP00278). Medicilon as a partner of Xuanzhu, provided KM501 with GLP-compliant preclinical research services based on the Medicilon Antibody Development Service Platform, including pharmacokinetic studies and safety evaluation.
More
Medicilon Assists Xuanzhu Biopharmaceutical's KM501, a First Double-antibody ADC Drug that Completely Knocks Out Fucose, has been Approved for Clinical Trials
Mar 03,2023
Medicilon assists Carephar first potassium-ion-competitive acid blocker "Carenoprazan Tablets" approved for sales in China
The Class 1 new drug Carenoprazan Hydrochloride Tablets, for the treatment of duodenal ulcer and reflux esophagitis, independently developed by Jiangsu Carephar was officially approved for sales in market. Medicilon has provided research and development from compound design to preclinical candidate compounds, as well as most of the in vitro H+K+-ATPase testing and other services and the Carenoprazan has been successfully approved.
More
Medicilon assists Carephar first potassium-ion-competitive acid blocker "Carenoprazan Tablets" approved for sales in China
Feb 24,2023
Medicilon Assists CGeneTech's Oral Hypoglycemic DPP-4 Inhibitor, New Drug Application (NDA) Accepted
CGeneTech submitted the DPP-4 inhibitor, for the treatment of type 2 diabetes, to the NMPA for approval. Medicilon, as a partner of CGeneTech, provided comprehensive preclinical research services in compliance with GLP regulations, including pharmacodynamic research, pharmacokinetic research and safety evaluation, as well as Phase I clinical bioanalysis to facilitate its efficient and high-quality R&D.
More
Medicilon Assists CGeneTech's Oral Hypoglycemic DPP-4 Inhibitor, New Drug Application (NDA) Accepted
Feb 17,2023
Medicilon Helps iMBioRay's CAR-raNK Cell Therapy Approved Clinical Trial
Recently, IBR854 Cell Injection of iMBioRay (Hangzhou) Biomedical Co., Ltd. (iMBioRay) obtained the permission of the NMPA for clinical trials. Shanghai Medicilon Inc. (Medicilon), as a partner of IBR854 Cell Injection, provides efficient, high-quality and comprehensive preclinical research services (including pharmacokinetic studies and safety evaluation) in compliance with GLP regulations. The IBR854 Cell Injection is successfully approved at the end.
More
Medicilon Helps iMBioRay's CAR-raNK Cell Therapy Approved Clinical Trial
Feb 03,2023
Medicilon 19th Anniversary
Medicilon welcome the year of 2023 and also welcome the 20th year of success. 19 years of overcoming obstacles, 19 years of non-stop innovation and 19 years of R&D acceleration, Medicilon, as a professional biopharmaceutical preclinical comprehensive R&D service CRO, covers the entire process of preclinical new drug research such as drug discovery, pharmaceutical research and preclinical research, in addition of expanding the CDMO service and the global development.
More
Medicilon 19th Anniversary
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(781)535-1428(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->